




UNIVERSITEIT • STELLENBOSCH • UNIVERSITY  
jou kennisvennoot • your knowledge partner



# DESMOND TUTU TB CENTRE

15 June 2016

**FRIEDA VERHEYE-DUA**


DESMOND TUTU TB CENTRE

DEPARTMENT of PAEDIATRICS AND CHILD HEALTH

FACULTY OF MEDICINE AND HEALTH SCIENCES

STELLENBOSCH UNIVERSITY
















**TYGERBERG HOSPITAL**



**SU FACULTY MEDICINES & HEALTH SCIENCES**



FACULTY OF MEDICINE AND HEALTH SCIENCES  
STELLENBOSCH UNIVERSITY



**Lower Ground level**

**DESMOND TUTU TB CENTRE**

**ADMIN HUB  
DATA CENTER**



## Stellenbosch University SUN Clinical trials Unit (CTU)

PI: Mark Cotton

CTU co-PIs: Anneke Hesseling, Andreas Diacon



### SUN CTU vision

Safe, effective, practical family-centered and integrated prevention, treatment and cure for HIV, TB and co-morbidities in individuals of all races, ages and gender, continuously refined through quality research, innovation and implementation

#### CRS I: FAM-CRU

CRS PI: Mark Cotton

CRS Coordinator: Joan Coetzee  
(IMPAACT & ACTG)

IMPAACT Study Coordinator: Lindee  
Ganger

ACTG study Coordinator: Charlotte  
Lawn

##### Focus areas

Pediatric HIV, maternal HIV, perinatal  
HIV transmission, adult HIV treatment,  
hepatitis, cervical cancer

##### Network involvement

IMPAACT, ACTG

##### Sites

Tygerberg Hospital

##### Satellite sites

Michael Mapongwana clinic  
Kraaifontein community clinic  
Bishop Lavis community clinic  
Elsiesrivier community clinic  
Bloekombos community clinic

#### CRS II: TASK

CRS PI: Andreas Diacon

CRS coordinator: Jeannine du Bois

##### Focus areas

Adult TB treatment, prevention,  
biomarkers

##### Network involvement

ACTG

##### Sites

Brooklyn Chest Hospital  
Delft community clinic  
Wallacedene clinic  
Mbwekweni

##### Satellite sites

Delft Community Health Centre  
Mfuleni Community Health Centre  
Scottsdene Clinic

#### CRS III: DTTC-SU

CRS PI: Anneke Hesseling

CRS coordinator: Frieda Verheye-Dua

##### Focus areas

Pediatric and maternal TB (treatment,  
diagnostic and vaccines)

##### Network involvement

IMPAACT

##### Sites

Brooklyn Chest Hospital  
Tygerberg Hospital

**Satellite sites** (future e.g. community  
prevention site)

Site B, Khayelitsha



**CRS LEADER - ANNEKE HESSELING**

**13 Clinicians / Sub-Investigators**

**CRS Coordinator/Regulatory**

**7 Study Coordinators/Project Managers**

**9 Study Nurses**

**9 Data Staff**

**3 Lab staff**

**12 Counselors (English/Afrikaans/Xhosa)**

**9 support staff**

**5 Drivers**




**Paediatric Team**

**69 staff**

Brooklyn Chest Hospital – 21 Km

Khayelitsha – 20 Km







UN-CTU  
SUN-CTU



*Stellenbosch University Clinical Trials Unit*



**PHARMACIES TASK & FAMCRU**

**DRIVERS & STAFF**

**LOGISTICS & COORDINATIONS**







# KARL BREMER HOSPITAL







# Khayelitsha Nolungile Clinic

## Site C



# Brooklyn Chest PK Unit














# Current IMPAACT Sites and TB Burden


FIGURE 2.5

Estimated TB incidence rates, 2012



# Risk of TB Disease and Death: Highest in the Youngest

- W Cape: TB notification >1000/100,000
- Annual risk of TB infection up to 4% in high-burden settings like SA
- Children < 5 and HIV- infected are at highest risk





## 14 October 2014 - Site approval as IMPAACT Site 31790

### **P1101**

Phase I/II Dose-Finding, Safety, Tolerance and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Children  $\geq 2$  Years to  $< 12$  Years of Age (Version 2.0 dated 19 June 2015)

Activation Protocol version 1.0 but study paused on 06 Feb 2015

**Activation Protocol version 2.0 on 17 February 2016**

**First PID Screened 13 June 2016 – enrollment 21 June 2016**

### **P1078**

A phase IV randomised double blind placebo-controlled trial to evaluate the safety of immediate (antepartum-initiated) versus deferred (postpartum-initiated) IPT in HIV-infected women in high TB incidence settings.

**Activation protocol version 1.0 on 22 June 2015**

**Enrolled 12 PIDs**

### **Phoenix feasibility study A5300**

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIX Trial Design

**Activation protocol 13 November 2015**

**Enrolled 14 Index +53 Household cases**



**Planned IMPAACT studies in near future:**

**P1026s**

Pharmacokinetic properties of antiretroviral and related drugs during pregnancy and postpartum

**P1108**

A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease.



# Multi-Drug Resistant TB (MDR TB)

- 500,000 new cases of MDR-TB in 2011
- 50,000 paediatric cases; 400,000 infections
- Data and formulations for treatment of MDR and XDR TB in children are lacking
- **MDR TB PK studies (observational), more than 300 kids in the past 4 year**
- P1108 and P2005



*WHO Global TB Report 2015*

*Jenkins HE et al. Lancet 2014; Dodd PJ et al. Lancet Global Health 2014*

Trial sponsor



Co-ordinating centre



Collaborating groups



## Shorter treatment for minimal TB in children

A randomised trial of therapy shortening for minimal tuberculosis with new WHO-recommended doses/ fixed-dose-combination drugs in African and Indian HIV+ and HIV- children

- Parallel group, non-inferiority trial
- 4 vs. 6 months, open label
- Children aged 0-16 years
- Non-severe TB
- WHO-recommended doses first-line drugs
- N=1200 children

Trial sponsor



Stellenbosch  
University,  
South Africa

Co-ordinating centre



MRC Clinical

Trials  
Unit at UCL,  
London, UK

## TB-CHAMP



A phase III cluster randomised placebo-controlled trial to assess the efficacy of **preventive therapy in child contacts of multidrug-resistant (MDR) tuberculosis (TB)**

- 814 households of adult MDR-TB source case (with on average 2 children per household)
- 192 weeks in total including enrolment over 72 weeks and follow-up for 96 weeks







**DTTC MISSION**  
**TO HAVE A TB FREE WORLD FOR THE NEXT GENERATION**



*"We call on the international community, which was so tremendous in its fight against another epidemic, apartheid, to show the same commitment to deal with TB and HIV/AIDS"*

